Metal-Oxo Containing Polymer Nanobeads As Potential Contrast Agents for Magnetic Resonance Imaging

Abstract

Magnetic resonance imaging (MRI) has greatly revolutionized the way diseases are detected and treated, as it is a non-invasive imaging modality solely based on the interaction of radiowaves and hydrogen nuclei in the presence of an external magnetic field. It is widely used today for the diagnosis of diseases as it offers an efficient method of mapping structure and function of soft tissues in the body. Most MRI examinations utilize paramagnetic materials known as contrast agents, which enhance the MR signal by decreasing the longitudinal (T1) and transverse (T2) relaxation times of the surrounding water protons in biological systems. This results into increased signal intensity differences thereby allowing better interpretation and analysis of pathological tissues. Contrast agents function by lowering the T1 or lowering the T2, resulting into bright and dark contrasts, respectively.

The most common MRI contrast agents that are in clinical use today are gadolinium chelates and superparamagnetic iron oxide nanoparticles, both of which have their own advantages in terms of contrast enhancement properties. In the past few years, however, there has been interest in utilizing metal-containing clusters for MRI contrast enhancement as these materials bridge the gap between the constrained structure and magnetic properties of the gadolinium chelates with the superparamagnetic behavior of the iron oxide nanoparticles. Recently, metallic clusters containing Mn and Fe metal centers have received increased attention mainly because of their potential for high spin states and benign nature.

In the quest to further develop novel imaging agents, this research has focused on investigating the use of metal-oxo clusters as potential contrast agents for MRI. The primary goal of this project is to identify clusters that meet the following criteria: high paramagnetic susceptibility, water-soluble, stable, cheap, contain environmentally benign metals, and easily derivatized. This work is also directed at developing metal-oxo containing hybrid materials using first row transition metals with potential catalytic and magnetic properties as well. We report several screened metal-oxo clusters but this study has centered on the mixed-metal oxo cluster, Mn8Fe4O12(O2CCH3)16(H2O)4 or Mn8Fe4, mainly because it is highly paramagnetic and is soluble and stable in water. The cluster was screened for potential MRI contrast and was found to be a very promising T2 contrast agent with relaxivity values of r1 = 2.3 mM-1s-1 and r2 = 29.5 mM-1s-1. Initial cell studies on two human prostate cancer cell lines, DU-145 and LNCap, reveal that the cluster has low cytotoxicity and may be potentially used in vivo.

One key advantage of Mn8Fe4 is its ability to undergo ligand exchange reactions, thus providing a mechanism for grafting to a variety of supports. By substituting the acetate groups on Mn8Fe4 with polymerizable ligands, we are able to form monodisperse magnetic polymer nanobeads (~70 nm diameter) via the miniemulsion polymerization technique. To render the nanobead suitable for future in vivo experiments, we coated the surface with biocompatible polysaccharide dextran (40 kDa). Interestingly, relaxivity measurements and MRI studies show that encapsulating the Mn8Fe4 core within a polymer matrix decreased T2 effects resulting in a positive T1 contrast enhancement. The resulting hybrid particles have the potential for further surface functionalization (i.e., therapeutic drugs, targeting moiety, fluorescent probe, etc.) making them a promising tool for biomedicine.